Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02669862 | A Study of A-101 Solution in Subjects With Common Warts. | PHASE2 | COMPLETED | 98 | — | — | Dec 21, 2015 | Sep 16, 2016 | Dec 7, 2018 | 1 | United States |
The primary effectiveness will consist of the mean change from Visit 2 to Visit 10 in Physician Wart Assessment (PWA) performed using Analysis of Covariance (ANCOVA) with Visit 2 PWA as the covariate. Physician Wart Analysis is a measurement scale from 0 to 3 that evaluates the wart with 0 being clear and 3 being clinically diagnosable wart that is raised, with an obviously rough surface.
| Arm | Type | Description |
|---|---|---|
| A-101 Solution 40 | EXPERIMENTAL | A-101 Solution 40% administered once per week |
| A-101 Solution 45 | EXPERIMENTAL | A-101 Solution 45% administered once per week |
| Vehicle Solution | PLACEBO_COMPARATOR | Vehicle Solution administered once per week |
| Name | Type | Description |
|---|---|---|
| A-101 Solution 40 | DRUG | - |
| A-101 Solution 45 | DRUG | - |
| Vehicle Solution | DRUG | - |
Inclusion Criteria: 1. Subject is at least 18 years of age 2. Subject has a clinical diagnosis of common warts 3. Subject has 1 appropriate Target Wart as defined below, on the trunk or extremities: * Have a longest axis that is 3mm to 10mm * Have a thickness ≤3mm * Be a discrete lesion ...